Yale University

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.

TitleDaclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.
Publication TypeJournal Article
Year of Publication2012
AuthorsPol, Stanislas, Reem H. Ghalib, Vinod K. Rustgi, Claudia Martorell, Greg T. Everson, Harvey A. Tatum, Christophe Hézode, Joseph K. Lim, Jean-Pierre Bronowicki, Gary A. Abrams, Norbert Bräu, David W. Morris, Paul J. Thuluvath, Robert W. Reindollar, Philip D. Yin, Ulysses Diva, Robert Hindes, Fiona McPhee, Dennis Hernandez, Megan Wind-Rotolo, Eric A. Hughes, and Steven Schnittman
JournalThe Lancet infectious diseases
Volume12
Issue9
Pagination671-7
Date Published2012 Sep
ISSN1474-4457
KeywordsAdult, Aged, Antiviral Agents, Double-Blind Method, Drug Therapy, Combination, Female, France, Genotype, Hepacivirus, Hepatitis C, Chronic, Humans, Imidazoles, Interferon-alpha, Male, Middle Aged, Placebos, Polyethylene Glycols, Recombinant Proteins, Ribavirin, RNA, Viral, Treatment Outcome, United States, Viral Load
AbstractSeveral direct-acting antivirals for chronic hepatitis C virus (HCV) infection are available, but they are limited by tolerability and dosing schedules. Once-daily daclatasvir, a potent NS5A replication complex inhibitor, was generally well tolerated in phase 1 studies. We assessed daclatasvir in combination with pegylated interferon (peginterferon) and ribavirin for chronic HCV.
DOI10.1353/hpu.2012.0006
Alternate JournalLancet Infect Dis

External Links